CDK inhibitors like Palbociclib have significantly advanced treatment for HR+, HER2-breast cancer by targeting CDK4 and CDK6 enzymes (Harbeck et al., 2021; Wang et al., 2024), crucial for cell proliferation (Nebenfuehr et al., 2020; Baker et al., 2022). This evidence concerns the gene ERBB2 and breast cancer.